Selected Grants
Long-term Follow-up to Evaluate the Safety of LX1001 in Participants with APOE4 Homozygote Alzheimer's Disease.
Clinical TrialPrincipal Investigator · Awarded by LEXEO Therapeutics, Inc · 2024 - 2029Biopsy-based single cell assays for olfactory sensory changes in an Alzheimer's Disease cohort
ResearchCo Investigator · Awarded by National Institute on Aging · 2024 - 2028Automated High-purity Exosome isolation-based AD diagnostics system (AHEADx)
ResearchCo-Principal Investigator · Awarded by National Institute on Aging · 2023 - 2028Retinal Light Scattering Measurements as a Clinical Biomarker of Alzheimer's Disease
ResearchCo Investigator · Awarded by National Institute on Aging · 2022 - 2027A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2023 - 2026Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2022 - 2026VRFCAT Content Validity
ResearchPrincipal Investigator · Awarded by Critical Path Institute · 2023 - 2025Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)
ResearchPrincipal Investigator · Awarded by American College of Radiology · 2023 - 2025A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Participants with APOE4 Homozygote Alzheimers Disease
Clinical TrialPrincipal Investigator · Awarded by LEXEO Therapeutics, Inc · 2022 - 2025Effects of Healthy Aging and Mild Cognitive Impairment on Memory Representations
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2025Cognitive Stimulation Therapy across a healthcare system to improve clinical outcomes
ResearchCollaborator · Awarded by Dementia Alliance of North Carolina · 2020 - 2022A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 52 Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by Cassava Sciences, Inc · 2022 - 2022External Relationships
- Eisai Pharmaceuticals
- PeerView
- University of Southern California
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.